Moonwalk Biosciences secures $70m Series B for adipose-targeted RNAi

Privately held Moonwalk Biosciences has completed an oversubscribed $70 million Series B financing co-led by Alpha Wave Ventures and YK Bioventures, with Eli Lilly and Company, Gaorong Ventures, ARCH Venture Partners, Khosla Ventures and Future Ventures participating. Proceeds will support IND-enabling work and the planned late-2027 first-in-human study of MW101, while funding additional tissue-targeted small interfering RNA programmes across obesity and cardiometabolic disease. Moonwalk launched in 2024 with $57 million of seed and Series A financing, meaning the company has now disclosed at least $127 million of outside funding since formation. That is substantial capital for a biotech whose lead obesity programme has not yet entered humans, making the next stage less about investor enthusiasm and more about whether adipose-specific RNA interference can reproduce its preclinical effects safely in people.

Moonwalk’s strategy differs from the incretin-based medicines dominating the obesity market. Instead of primarily reducing appetite, its programmes are designed to deliver siRNA directly into adipose tissue and modulate pathways involved in energy homeostasis, adipogenesis, lipolysis and thermogenesis. The company says preclinical experiments have reduced body weight and fat mass while preserving lean mass without lowering food intake, while non-human primate work showed adipose target engagement after one dose consistent with the possibility of quarterly or twice-yearly administration. These are company-reported preclinical findings and should not be treated as evidence that humans will experience the same weight loss, muscle preservation or dosing durability.

Why is Moonwalk targeting fat tissue instead of trying to suppress appetite?

Current GLP-1 and related incretin therapies achieve substantial weight loss partly by reducing appetite and food intake. That mechanism has transformed obesity treatment but can also produce gastrointestinal adverse effects and loss of lean tissue alongside fat.

Moonwalk is pursuing a different biological strategy. Tissue-targeted siRNA can silence selected genes inside adipose cells, potentially changing how fat tissue stores, mobilizes or consumes energy without making appetite suppression the primary therapeutic mechanism.

That creates a potentially complementary rather than purely competitive opportunity. An adipose-targeted drug could theoretically be used in patients unable to tolerate incretins, after patients discontinue them or eventually in combination strategies where appetite reduction and adipose biology are addressed separately.

The word theoretically is crucial. Moonwalk has not yet shown that its approach produces safe or clinically meaningful weight loss in humans. Directly modifying adipose biology can create different risks from incretins, and the importance of target selection will become much clearer only when MW101 enters clinical testing.

Why could preserving lean mass become commercially important in the obesity market?

Weight-loss percentages often combine losses of fat and lean tissue. Patients and physicians increasingly care about body composition because skeletal muscle affects strength, metabolic health and physical function, particularly in older people.

Moonwalk says its preclinical programmes have reduced fat mass while preserving lean muscle, giving the company a differentiation thesis that goes beyond headline percentage weight loss.

If that effect survives human testing, a therapy producing somewhat less total weight loss but better body composition could still have clinical value. The market increasingly includes patients who have already used powerful incretin medicines, making maintenance of muscle and durability of weight control relevant next-generation development goals.

Body-composition advantage will need objective proof through imaging or other validated measures. Investors should therefore avoid assuming the lean-mass claim has been established simply because it appeared consistently in preclinical development.

How meaningful is Eli Lilly’s participation in the Series B?

Eli Lilly’s participation gives Moonwalk a strategic investor with exceptional obesity-market expertise. Lilly markets major incretin medicines and has been actively investing across next-generation metabolic technologies, making its presence in the round a form of external industry validation.

It should not be interpreted as a commercial partnership or acquisition agreement. Moonwalk did not announce licensing rights, an option arrangement or an exclusive development relationship with Lilly.

The financing remains venture capital, meaning Lilly and the other investors are accepting substantial development risk. Moonwalk still has to complete IND-enabling work, gain regulatory permission to enter the clinic and demonstrate human safety before efficacy becomes a meaningful question.

The investor list nevertheless matters because a private company trying to reach first-in-human development needs both capital and specialized knowledge. Alpha Wave, YK Bioventures, existing life-science investors and Lilly give Moonwalk a strong financing syndicate going into an expensive translational stage.

Is $127 million of disclosed financing enough to take Moonwalk through proof of concept?

Moonwalk’s original $57 million financing and new $70 million Series B total $127 million of disclosed capital since launch. That is not the same as current cash because the company has been operating and investing since 2024, while financing rounds can include capital deployed over time.

The Series B is specifically intended to complete IND-enabling work, advance MW101 into first-in-human development and expand other siRNA programmes. The company has not disclosed valuation, cash burn or projected runway, preventing an outside calculation of how far the $70 million extends beyond the initial clinical study.

A late-2027 first-in-human start leaves more than a year of preclinical and regulatory work ahead. Manufacturing, toxicology and chemistry programmes can expose issues that delay an IND even before the first participant is dosed.

The funding nevertheless reduces near-term financing risk. Moonwalk does not need to prove human efficacy immediately to remain operational; it needs to use the new capital to reach the clinic with enough resources left to generate interpretable early data.

What would turn Moonwalk from an interesting obesity platform into a credible drug developer?

The first milestone is successful IND-enabling toxicology. An adipose-targeting chemistry needs to reach fat tissue selectively without accumulating at harmful levels in liver, kidney or other organs.

Human pharmacokinetics and target engagement then become crucial. The company’s prediction of quarterly or twice-yearly dosing is based on non-human primate work, not human evidence.

Early clinical studies also need to demonstrate that the mechanism affects body composition rather than merely molecular biomarkers. Preservation of lean mass would be particularly valuable if confirmed alongside meaningful fat reduction.

Moonwalk has built enough capital and scientific credibility to test a differentiated obesity thesis. The Series B does not resolve whether that thesis works. It buys the company the opportunity to answer the question in humans.

Key takeaways on Moonwalk Biosciences’ $70 million Series B

• Moonwalk Biosciences has secured an oversubscribed $70 million Series B.
• Alpha Wave Ventures and YK Bioventures co-led the financing.
• Eli Lilly participated alongside new and existing investors.
• Moonwalk launched with $57 million of seed and Series A capital in 2024.
• Total disclosed financing therefore reaches at least $127 million.
• MW101 is the company’s lead obesity candidate.
• First-in-human development is targeted for late 2027.
• Moonwalk is developing adipose-targeted siRNA rather than an appetite-focused incretin.
• Preclinical findings suggest fat-mass reduction with lean-mass preservation, but those results have not been demonstrated in humans.
• Human safety, target engagement and body-composition data are the next meaningful validation points.